Monitoring Anticoagulation and Inflammation in Adults After Heart and Vascular Surgery to Improve Safety and Outcomes

What this Trial Is About

Researchers are investigating the best way to monitor anticoagulation in patients receiving unfractionated heparin UFH after major heart and vascular surgeries. The study aims to compare different anticoagulation monitoring methods such as activated clotting time ACT, activated partial thromboplastin time aPTT, viscoelastic tests ROTEM, and anti-factor Xa levels. It also explores the relationship between inflammation, anticoagulation levels, adverse events like bleeding or thrombosis, and the occurrence of delirium after these surgeries. Patients undergoing heart surgery require full heparinization before using the heart-lung machine, with monitoring done during and after surgery using ACT and other tests. Those undergoing vascular surgery receive UFH intraoperatively and sometimes continuous infusion postoperatively. The study evaluates various monitoring tools in real-time to assess anticoagulation levels, inflammation markers, and related complications. Some patients receiving extracorporeal membrane oxygenation ECMO support are also included, with close monitoring of their anticoagulation needs. Participants will be followed for up to 30 days after surgery to track adverse events such as bleeding, thrombosis, inflammation, delirium, and the need for additional treatments like protamine. The study collects data from blood tests, coagulation monitoring tools, and clinical assessments to understand the links between anticoagulation, inflammation, and patient outcomes. This observational study does not involve experimental treatments but gathers detailed information to improve monitoring approaches.

Anticoagulation and Inflammation Monitoring in Patients After Heart and Vascular Interventions